查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2000459

太空生物學和多體學市場預測至2034年——按產品、組件、技術、體學類型、應用和地區分類的全球分析

Spatial Biology & Multi-Omics Market Forecasts to 2034 - Global Analysis By Product, By Component, By Technology, By Omics Type, By Application and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球空間生物學和多組體學市場將達到 3.3998 億美元，並在預測期內以 10.6% 的複合年成長率成長，到 2034 年達到 8.4189 億美元。

空間生物學和多組體學是指在保持生物分子（例如DNA、RNA、蛋白質和代謝物）在組織和細胞內空間排列不變的情況下，分析這些生物分子的綜合技術。這些方法結合了基因組學、轉錄組學、蛋白質組學和代謝體學以及空間映射工具，以闡明複雜生物系統中分子相互作用的發生機制。這項技術有助於更深入地了解疾病機制、腫瘤微環境和細胞異質性。太空生物學和多體學平台正日益廣泛地應用於精準醫療、生物標記發現和藥物研發，幫助研究人員在自然生物學環境中可視化分子活性和相互作用。

精準醫療檢測的需求日益成長

精準醫療致力於根據個體的基因、分子和細胞特徵最佳化治療方法。太空生物學技術使研究人員能夠在組織的空間環境中研究基因表現和蛋白質-蛋白質相互作用。這使得科學家能夠更深入地了解細胞層面的疾病機制。製藥和生物技術公司正擴大利用這些技術來識別治療標靶並開發個人化療法。隨著醫療保健轉向更加以患者為中心的治療策略轉變，空間生物學和多體學技術的應用也不斷成長。

複雜數據的分析與解釋

複雜的數據技術會產生龐大且高度複雜的資料集，這些資料集融合了基因組、轉錄組、蛋白質組和空間資訊。解讀這類多維資料需要先進的運算工具和專業知識。許多研究機構在有效整合和分析這些數據方面面臨挑戰。缺乏標準化的資料處理流程進一步加劇了這個過程的複雜性。因此，資料管理的複雜性可能會阻礙空間生物學和多體學平台的廣泛應用。

腫瘤學和生物標記發現領域的拓展

在癌症研究中，了解腫瘤微環境和細胞異質性變得日益重要。太空生物學技術使研究人員能夠分析癌細胞如何與周圍組織和免疫細胞相互作用，從而為識別新的生物標記和治療標靶提供寶貴的見解。多體學整合進一步增強了檢測疾病特異性分子特徵的能力。製藥公司正積極投資這些技術，以改善癌症的診斷和治療方法研發。隨著腫瘤學研究在全球的擴展，對空間生物學解決方案的需求預計將會成長。

熟練的生物資訊專家短缺

處理多體學數據需要計算生物學、資料科學和高級統計分析的專業知識。然而，具備管理和解讀這些複雜資料集所需技能的人才儲備有限。這種人才短缺會減緩研究進展，並限制太空生物學技術的有效應用。許多機構在培訓能夠操作高階分析工具的人員方面也面臨挑戰。如果沒有足夠的專業知識，這些技術的潛在優勢可能無法充分發揮。

新冠疫情的影響：

新冠疫情對空間生物學和多組體學市場產生了重大影響。研究人員利用多組體學技術研究了SARS-CoV-2感染和免疫反應的分子機制。太空生物學工具幫助科學家了解病毒如何影響各種組織和細胞類型。這促使人們對先進的體學技術產生了更大的研究興趣，並獲得了更多資金支持。然而，疫情造成的干擾最初導致許多機構的實驗室運作和研究活動延誤。整體而言，疫情加速了先進生物分析技術在感染疾病研究的應用。

在預測期內，空間轉錄組學平台細分市場預計將成為最大的細分市場。

預計在預測期內，空間轉錄組學平台將佔據最大的市場佔有率。這是因為這些平台能夠對組織樣本中的基因表現進行高解析度映射。研究人員可以在維持組織環境空間背景的同時，分析特定細胞中基因的表現。這種能力在研究癌症、神經系統疾病和發炎性疾病等複雜疾病方面尤其有用。製藥公司和學術機構正在廣泛利用空間轉錄組學進行生物標記發現和治療標靶識別。此外，該技術還有助於與其他體學方法整合，從而獲得更深入的生物學見解。

在預測期內，藥物研發領域預計將呈現最高的複合年成長率。

在預測期內，藥物發現領域預計將呈現最高的成長率，這主要得益於太空生物學和多體學技術在藥物研發中日益廣泛的應用。這些技術有助於闡明疾病機制、驗證藥物標靶，並更精準地檢驗治療反應。整合多組體學資料能夠幫助研究人員更深入了解疾病相關的複雜生物學路徑。製藥公司正擴大將空間分析融入其臨床前和轉化研究流程，這不僅提高了藥物發現的效率，也降低了臨床試驗失敗的風險。

市佔率最大的地區：

在預測期內，北美預計將佔據最大的市場佔有率，這主要得益於其強大的研究基礎設施以及在生物技術和基因組學領域的大量投資。該地區匯聚了許多主要企業、製藥公司和學術研究機構。政府資助和私人投資為基於體學的研究舉措提供了強力的支持。此外，先進的定序技術和生物資訊學專業知識的普及正在加速太空生物學領域的創新。產業界和學術機構之間的許多合作也促進了技術進步。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率，這主要得益於生技產業的擴張和生命科學研究投資的增加。中國、日本、韓國和印度等國家正在加強其在基因組學和生物醫學研究方面的能力。該地區各國政府正透過資助計畫和創新舉措支持體學研究。製藥和生物技術公司數量的不斷成長也促進了先進研究技術的應用。此外，人們健康意識的提高和對精準醫療的需求也在加速市場成長。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要企業進行SWOT分析（最多3家公司）
  • 區域分類
    • 應客戶要求，我們提供主要國家和地區的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對主要企業進行基準分析。

目錄

第1章執行摘要

  • 市場概覽及主要亮點
  • 促進因素、挑戰與機遇
  • 競爭格局概述
  • 戰略洞察與建議

第2章：研究框架

  • 研究目標和範圍
  • 相關人員分析
  • 研究假設和限制
  • 調查方法

第3章 市場動態與趨勢分析

  • 市場定義與結構
  • 主要市場促進因素
  • 市場限制與挑戰
  • 投資成長機會和重點領域
  • 產業威脅與風險評估
  • 技術與創新展望
  • 新興市場/高成長市場
  • 監管和政策環境
  • 新冠疫情的影響及復甦前景

第4章：競爭環境與策略評估

  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭公司之間的競爭
  • 主要企業市佔率分析
  • 產品基準評效和效能比較

第5章 全球空間生物學與多體學市場：依產品分類

  • 空間轉錄組學平台
  • 空間基因組系統
  • 空間蛋白質體學平台
  • 多體學整合平台
  • 其他產品

第6章 全球空間生物學與多體學市場：依組件分類

  • 裝置
  • 試劑和試劑盒
  • 消耗品
  • 軟體
  • 其他規則

第7章 全球空間生物學與多體學市場：依技術分類

  • 次世代定序
  • 原位雜合反應
  • 質譜成像
  • 多重螢光
  • 人工智慧與多體學的整合
  • 其他技術

第8章 全球空間生物學與多體學市場：按體學類型分類

  • 基因組學
  • 轉錄組學
  • 蛋白質體學
  • 代謝體學
  • 其他體學類型

第9章 全球空間生物學與多體學市場：按應用分類

  • 腫瘤學調查
  • 神經學檢查
  • 免疫學調查
  • 藥物發現
  • 生物標記發現
  • 其他用途

第10章 全球空間生物學與多體學市場：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 比利時
    • 瑞典
    • 瑞士
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 馬來西亞
    • 新加坡
    • 越南
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
    • 秘魯
    • 其他南美國家
  • 世界其他地區（RoW）
    • 中東
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 以色列
      • 其他中東國家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲國家

第11章 策略市場資訊

  • 工業價值網路和供應鏈評估
  • 空白區域和機會地圖
  • 產品演進與市場生命週期分析
  • 通路、經銷商和打入市場策略的評估

第12章 產業趨勢與策略舉措

  • 併購
  • 夥伴關係、聯盟和合資企業
  • 新產品發布和認證
  • 擴大生產能力和投資
  • 其他策略舉措

第13章：公司簡介

  • 10x Genomics, Inc.
  • NanoString Technologies, Inc.
  • Illumina, Inc.
  • Akoya Biosciences, Inc.
  • Thermo Fisher Scientific Inc.
  • Bruker Corporation
  • Standard BioTools Inc.
  • BGI Genomics
  • Parse Biosciences
  • Lunaphore Technologies SA
  • Olink Holding AB
  • Oxford Nanopore Technologies plc
  • SciLifeLab
  • Visium Diagnostics
  • ImmunoGenomics, Inc.
Product Code: SMRC34505

According to Stratistics MRC, the Global Spatial Biology & Multi-Omics Market is accounted for $339.98 million in 2026 and is expected to reach $841.89 million by 2034 growing at a CAGR of 10.6% during the forecast period. Spatial Biology & Multi-Omics refers to integrated technologies that analyze biological molecules such as DNA, RNA, proteins, and metabolites-while preserving their spatial organization within tissues or cells. These approaches combine genomics, transcriptomics, proteomics, and metabolomics with spatial mapping tools to reveal how molecular interactions occur within complex biological systems. The technology enables deeper understanding of disease mechanisms, tumor microenvironments, and cellular heterogeneity. Spatial biology and multi-omics platforms are increasingly used in precision medicine, biomarker discovery, and drug development, helping researchers visualize molecular activity and interactions within their natural biological context.

Market Dynamics:

Driver:

Growing demand for precision medicine research

Precision medicine focuses on tailoring treatments based on an individual's genetic, molecular, and cellular characteristics. Spatial biology technologies allow researchers to study gene expression and protein interactions within the spatial context of tissues. This helps scientists better understand disease mechanisms at a cellular level. Pharmaceutical and biotechnology companies are increasingly using these technologies to identify therapeutic targets and develop personalized therapies. As healthcare shifts toward more patient-specific treatment strategies, the adoption of spatial biology and multi-omics technologies continues to rise.

Restraint:

Complex data analysis and interpretation

Complex data technologies generate massive and highly complex datasets that combine genomic, transcriptomic, proteomic, and spatial information. Interpreting such multidimensional data requires advanced computational tools and specialized expertise. Many research institutions face challenges in integrating and analyzing this data effectively. The lack of standardized data processing pipelines further complicates the process. As a result, the complexity of data management can limit the widespread adoption of spatial biology and multi-omics platforms.

Opportunity:

Expansion in oncology and biomarker discovery

Cancer research increasingly relies on understanding tumor microenvironments and cellular heterogeneity. Spatial biology technologies enable researchers to analyze how cancer cells interact with surrounding tissues and immune cells. This provides valuable insights for identifying novel biomarkers and therapeutic targets. Multi-omics integration further enhances the ability to detect disease-specific molecular signatures. Pharmaceutical companies are actively investing in these technologies to improve cancer diagnosis and treatment development. As oncology research expands globally, demand for spatial biology solutions is expected to increase.

Threat:

Limited skilled bioinformatics professionals

Handling multi-omics data requires expertise in computational biology, data science, and advanced statistical analysis. However, there is a limited workforce with the necessary skills to manage and interpret these complex datasets. This shortage can slow research progress and limit the effective use of spatial biology technologies. Many organizations also face challenges in training personnel to operate sophisticated analytical tools. Without adequate expertise, the potential benefits of these technologies may not be fully realized.

Covid-19 Impact:

The COVID-19 pandemic had a notable impact on the Spatial Biology & Multi-Omics market. Researchers used multi-omics technologies to study the molecular mechanisms of SARS-CoV-2 infection and immune responses. Spatial biology tools helped scientists understand how the virus affected different tissues and cell types. This increased research interest and funding for advanced omics technologies. However, pandemic-related disruptions initially slowed laboratory operations and research activities in many institutions. Overall, the pandemic accelerated the adoption of advanced biological analysis technologies in infectious disease research.

The spatial transcriptomics platforms segment is expected to be the largest during the forecast period

The spatial transcriptomics platforms segment is expected to account for the largest market share during the forecast period as these platforms enable high-resolution mapping of gene expression within tissue samples. Researchers can analyze how genes are expressed in specific cells while preserving the spatial context of the tissue environment. This capability is particularly valuable in studying complex diseases such as cancer, neurological disorders, and inflammatory conditions. Pharmaceutical companies and academic institutions widely use spatial transcriptomics for biomarker discovery and therapeutic target identification. The technology also supports integration with other omics approaches for deeper biological insights.

The drug development segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the drug development segment is predicted to witness the highest growth rate due to increasing use of spatial biology and multi-omics technologies in pharmaceutical research. These technologies help identify disease mechanisms, validate drug targets, and monitor therapeutic responses more accurately. Integrating multi-omics data allows researchers to better understand complex biological pathways involved in diseases. Pharmaceutical companies are increasingly incorporating spatial analysis into preclinical and translational research workflows. This improves the efficiency of drug discovery and reduces the risk of clinical trial failures.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share owing to strong research infrastructure and high investments in biotechnology and genomics. The region hosts many leading biotechnology companies, pharmaceutical firms, and academic research institutions. Government funding and private investments strongly support omics-based research initiatives. Additionally, the presence of advanced sequencing technologies and bioinformatics expertise accelerates innovation in spatial biology. Numerous collaborations between industry and academic organizations also contribute to technological advancements.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR driven by expanding biotechnology industries and increasing investments in life science research. Countries such as China, Japan, South Korea, and India are strengthening their genomic and biomedical research capabilities. Governments across the region are supporting omics research through funding programs and innovation initiatives. The rising number of pharmaceutical and biotechnology companies is also contributing to the adoption of advanced research technologies. Additionally, growing healthcare awareness and demand for precision medicine are accelerating market growth.

Key players in the market

Some of the key players in Spatial Biology & Multi-Omics Market include 10x Genomics, Inc., NanoString Technologies, Inc., Illumina, Inc., Akoya Biosciences, Inc., Thermo Fisher Scientific Inc., Bruker Corporation, Standard BioTools Inc., BGI Genomics, Parse Biosciences, Lunaphore Technologies SA, Olink Holding AB, Oxford Nanopore Technologies plc, SciLifeLab, Visium Diagnostics and ImmunoGenomics, Inc.

Key Developments:

In January 2026, 10x Genomics entered a strategic collaboration with CareDx to launch ImmuneScape, a multiomics research initiative. The program will use 10x's Xenium spatial and Chromium Flex single cell platforms to create high-resolution maps of immune mechanisms in transplant rejection, aiming to advance personalized transplant medicine.

In May 2024, Bruker Corporation completed its acquisition of NanoString Technologies for $392.6 million in cash, buying the assets and rights associated with the company after NanoString filed for bankruptcy . This strategic acquisition was aimed at bolstering Bruker's portfolio in the rapidly growing spatial biology market by integrating NanoString's CosMx and GeoMx spatial platforms.

Products Covered:

  • Spatial Transcriptomics Platforms
  • Spatial Genomics Systems
  • Spatial Proteomics Platforms
  • Multi-Omics Integration Platforms
  • Other Products

Components Covered:

  • Instruments
  • Reagents & Kits
  • Consumables
  • Software
  • Other Components

Technologies Covered:

  • Next-Generation Sequencing
  • In Situ Hybridization
  • Mass Spectrometry Imaging
  • Multiplexed Immunofluorescence
  • AI & Multi-Omics Integration
  • Other Technologies

Omic Types Covered:

  • Genomics
  • Transcriptomics
  • Proteomics
  • Metabolomics
  • Other Omic Types

Applications Covered:

  • Oncology Research
  • Neurology Research
  • Immunology Research
  • Drug Development
  • Biomarker Discovery
  • Other Applications

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Spatial Biology & Multi-Omics Market, By Product

  • 5.1 Spatial Transcriptomics Platforms
  • 5.2 Spatial Genomics Systems
  • 5.3 Spatial Proteomics Platforms
  • 5.4 Multi-Omics Integration Platforms
  • 5.5 Other Products

6 Global Spatial Biology & Multi-Omics Market, By Component

  • 6.1 Instruments
  • 6.2 Reagents & Kits
  • 6.3 Consumables
  • 6.4 Software
  • 6.5 Other Components

7 Global Spatial Biology & Multi-Omics Market, By Technology

  • 7.1 Next-Generation Sequencing
  • 7.2 In Situ Hybridization
  • 7.3 Mass Spectrometry Imaging
  • 7.4 Multiplexed Immunofluorescence
  • 7.5 AI & Multi-Omics Integration
  • 7.6 Other Technologies

8 Global Spatial Biology & Multi-Omics Market, By Omics Type

  • 8.1 Genomics
  • 8.2 Transcriptomics
  • 8.3 Proteomics
  • 8.4 Metabolomics
  • 8.5 Other Omics Types

9 Global Spatial Biology & Multi-Omics Market, By Application

  • 9.1 Oncology Research
  • 9.2 Neurology Research
  • 9.3 Immunology Research
  • 9.4 Drug Development
  • 9.5 Biomarker Discovery
  • 9.6 Other Applications

10 Global Spatial Biology & Multi-Omics Market, By Geography

  • 10.1 North America
    • 10.1.1 United States
    • 10.1.2 Canada
    • 10.1.3 Mexico
  • 10.2 Europe
    • 10.2.1 United Kingdom
    • 10.2.2 Germany
    • 10.2.3 France
    • 10.2.4 Italy
    • 10.2.5 Spain
    • 10.2.6 Netherlands
    • 10.2.7 Belgium
    • 10.2.8 Sweden
    • 10.2.9 Switzerland
    • 10.2.10 Poland
    • 10.2.11 Rest of Europe
  • 10.3 Asia Pacific
    • 10.3.1 China
    • 10.3.2 Japan
    • 10.3.3 India
    • 10.3.4 South Korea
    • 10.3.5 Australia
    • 10.3.6 Indonesia
    • 10.3.7 Thailand
    • 10.3.8 Malaysia
    • 10.3.9 Singapore
    • 10.3.10 Vietnam
    • 10.3.11 Rest of Asia Pacific
  • 10.4 South America
    • 10.4.1 Brazil
    • 10.4.2 Argentina
    • 10.4.3 Colombia
    • 10.4.4 Chile
    • 10.4.5 Peru
    • 10.4.6 Rest of South America
  • 10.5 Rest of the World (RoW)
    • 10.5.1 Middle East
      • 10.5.1.1 Saudi Arabia
      • 10.5.1.2 United Arab Emirates
      • 10.5.1.3 Qatar
      • 10.5.1.4 Israel
      • 10.5.1.5 Rest of Middle East
    • 10.5.2 Africa
      • 10.5.2.1 South Africa
      • 10.5.2.2 Egypt
      • 10.5.2.3 Morocco
      • 10.5.2.4 Rest of Africa

11 Strategic Market Intelligence

  • 11.1 Industry Value Network and Supply Chain Assessment
  • 11.2 White-Space and Opportunity Mapping
  • 11.3 Product Evolution and Market Life Cycle Analysis
  • 11.4 Channel, Distributor, and Go-to-Market Assessment

12 Industry Developments and Strategic Initiatives

  • 12.1 Mergers and Acquisitions
  • 12.2 Partnerships, Alliances, and Joint Ventures
  • 12.3 New Product Launches and Certifications
  • 12.4 Capacity Expansion and Investments
  • 12.5 Other Strategic Initiatives

13 Company Profiles

  • 13.1 10x Genomics, Inc.
  • 13.2 NanoString Technologies, Inc.
  • 13.3 Illumina, Inc.
  • 13.4 Akoya Biosciences, Inc.
  • 13.5 Thermo Fisher Scientific Inc.
  • 13.6 Bruker Corporation
  • 13.7 Standard BioTools Inc.
  • 13.8 BGI Genomics
  • 13.9 Parse Biosciences
  • 13.10 Lunaphore Technologies SA
  • 13.11 Olink Holding AB
  • 13.12 Oxford Nanopore Technologies plc
  • 13.13 SciLifeLab
  • 13.14 Visium Diagnostics
  • 13.15 ImmunoGenomics, Inc.

List of Tables

  • Table 1 Global Spatial Biology & Multi-Omics Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Spatial Biology & Multi-Omics Market, By Product (2023-2034) ($MN)
  • Table 3 Global Spatial Biology & Multi-Omics Market, By Spatial Transcriptomics Platforms (2023-2034) ($MN)
  • Table 4 Global Spatial Biology & Multi-Omics Market, By Spatial Genomics Systems (2023-2034) ($MN)
  • Table 5 Global Spatial Biology & Multi-Omics Market, By Spatial Proteomics Platforms (2023-2034) ($MN)
  • Table 6 Global Spatial Biology & Multi-Omics Market, By Multi-Omics Integration Platforms (2023-2034) ($MN)
  • Table 7 Global Spatial Biology & Multi-Omics Market, By Other Products (2023-2034) ($MN)
  • Table 8 Global Spatial Biology & Multi-Omics Market, By Component (2023-2034) ($MN)
  • Table 9 Global Spatial Biology & Multi-Omics Market, By Instruments (2023-2034) ($MN)
  • Table 10 Global Spatial Biology & Multi-Omics Market, By Reagents & Kits (2023-2034) ($MN)
  • Table 11 Global Spatial Biology & Multi-Omics Market, By Consumables (2023-2034) ($MN)
  • Table 12 Global Spatial Biology & Multi-Omics Market, By Software (2023-2034) ($MN)
  • Table 13 Global Spatial Biology & Multi-Omics Market, By Other Components (2023-2034) ($MN)
  • Table 14 Global Spatial Biology & Multi-Omics Market, By Technology (2023-2034) ($MN)
  • Table 15 Global Spatial Biology & Multi-Omics Market, By Next-Generation Sequencing (2023-2034) ($MN)
  • Table 16 Global Spatial Biology & Multi-Omics Market, By In Situ Hybridization (2023-2034) ($MN)
  • Table 17 Global Spatial Biology & Multi-Omics Market, By Mass Spectrometry Imaging (2023-2034) ($MN)
  • Table 18 Global Spatial Biology & Multi-Omics Market, By Multiplexed Immunofluorescence (2023-2034) ($MN)
  • Table 19 Global Spatial Biology & Multi-Omics Market, By AI & Multi-Omics Integration (2023-2034) ($MN)
  • Table 20 Global Spatial Biology & Multi-Omics Market, By Other Technologies (2023-2034) ($MN)
  • Table 21 Global Spatial Biology & Multi-Omics Market, By Omics Type (2023-2034) ($MN)
  • Table 22 Global Spatial Biology & Multi-Omics Market, By Genomics (2023-2034) ($MN)
  • Table 23 Global Spatial Biology & Multi-Omics Market, By Transcriptomics (2023-2034) ($MN)
  • Table 24 Global Spatial Biology & Multi-Omics Market, By Proteomics (2023-2034) ($MN)
  • Table 25 Global Spatial Biology & Multi-Omics Market, By Metabolomics (2023-2034) ($MN)
  • Table 26 Global Spatial Biology & Multi-Omics Market, By Other Omics Types (2023-2034) ($MN)
  • Table 27 Global Spatial Biology & Multi-Omics Market, By Application (2023-2034) ($MN)
  • Table 28 Global Spatial Biology & Multi-Omics Market, By Oncology Research (2023-2034) ($MN)
  • Table 29 Global Spatial Biology & Multi-Omics Market, By Neurology Research (2023-2034) ($MN)
  • Table 30 Global Spatial Biology & Multi-Omics Market, By Immunology Research (2023-2034) ($MN)
  • Table 31 Global Spatial Biology & Multi-Omics Market, By Drug Development (2023-2034) ($MN)
  • Table 32 Global Spatial Biology & Multi-Omics Market, By Biomarker Discovery (2023-2034) ($MN)
  • Table 33 Global Spatial Biology & Multi-Omics Market, By Other Applications (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) are also represented in the same manner as above.